CyGene’s StrokeScan analyzes genes that have been associated with the increased risk of stroke and the ‘alpha-galactosidase A’ gene that is responsible for Fabry disease.
The StrokeScan is said to be based on know-how and intellectual properties that CyGene exclusively licensed from Arndt Rolfs of the University of Rostock, Germany.
Martin Munzer, president and CEO of CyGene, said: “StrokeScan has the ability to save lives. Genetic screening of people in high risk groups is essential in order to identify and then diagnose Fabry disease accurately and at an early stage.”